TIAGO KENJI TAKAHASHI

Índice h a partir de 2011
6
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor: MAK, Milena Perez ×

Resultados de Busca

Agora exibindo 1 - 10 de 17
  • bookPart
    Princípios do tratamento oncológico
    (2017) BRAGA, Henrique Faria; MAK, Milena Perez; TAKAHASHI, Tiago Kenji
  • bookPart
    Inibidores de tirosina-quinase
    (2013) TAKAHASHI, Tiago Kenji; MAK, Milena Perez; FERRARI, Anezka Carvalho Rubin de Celis; HOFF, Paulo Marcelo Gehm
  • bookPart
    Neoplasia de sítio primário indeterminado
    (2017) MAK, Milena Perez; TAKAHASHI, Tiago Kenji; SARAGIOTTO, Daniel Fernandes
  • bookPart
    Princípios do tratamento oncológico
    (2015) TAKAHASHI, Tiago Kenji; MAK, Milena Perez
  • bookPart
    Neoplasias de sítio primário indeterminado
    (2015) MAK, Milena Perez; TAKAHASHI, Tiago Kenji; SARAGIOTTO, Daniel Fernandes
  • bookPart
    Neutropenia febril
    (2015) MAK, Milena Perez; TAKAHASHI, Tiago Kenji
  • bookPart
    Câncer de pulmão
    (2017) FêDE, Angelo Bezerra de Souza; TAKAHASHI, Tiago Kenji; MAK, Milena Perez; CASTRO JUNIOR, Gilberto de
  • bookPart
    Tumores do trato gastrointestinal
    (2015) FERRARI, Anezka Carvalho Rubin de Celis; MAK, Milena Perez; TAKAHASHI, Tiago Kenji; SARAGIOTTO, Daniel Fernandes; SABBAGA, Jorge
  • article 7 Citação(ões) na Scopus
    Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers
    (2020) MAK, Milena Perez; PASINI, Fatima Solange; DIAO, Lixia; GARCIA, Fabyane O. Teixeira; TAKAHASHI, Tiago Kenji; NAKAZOTO, Denyei; MARTINS, Renata Eiras; ALMEIDA, Cristiane Maria; KULCSAR, Marco Aurelio Vamondes; LAMOUNIER, Valdelania Aparecida; NUNES, Emily Montosa; SOUZA, Isabela Cristina de; GARCIA, Marcio Ricardo Taveira; AMADIO, Alex Vieira; SIQUEIRA, Sheila Aparecida C.; SNITCOVSKY, Igor Moyses Longo; SICHERO, Laura; WANG, Jing; JR, Gilberto de Castro
    Background: Cisplatin-based chemoradiation (CCRT) offers locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients high local control rate, however, relapses are frequent. Our goal was to evaluate if association of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, with CCRT improved response rate (RR) and associated biomarkers. Methods: This phase II trial included patients with unresectable locally advanced (LA) oropharynx (OP) squamous cell carcinoma. CCRT began after 2 weeks of VPA (P1). Primary goal was RR at 8 weeks after chemoradiation (CRT)+VPA (P2). Biomarkers included microRNA (miR) polymerase chain reaction (PCR)-array profiling in plasma compared to healthy controls by two-sample t-test. Distribution of p-values was analysed by beta-uniform mixture. Findings were validated by real-time PCR quantitative polymerase chain reaction (qPCR) for selected miRs in plasma and saliva. p16, HDAC2 and RAD23 Homolog B, Nucleotide Excision Repair Protein (HR23B) tumour immunohistochemistry were evaluated. Results: Given significant toxicities, accrual was interrupted after inclusion of ten LA p16 negative OP patients. All were male, smokers/ex-smokers, aged 41-65 and with previous moderate/high alcohol intake. Nine evaluable patients yielded a RR of 88%. At false discovery rate of 5%, 169 miRs were differentially expressed between patients and controls, including lower expression of tumour suppressors (TSs) such as miR-31, -222, -let-7a/b/e and -145. miR-let-7a/e expression was validated by qPCR using saliva. A HDAC2 H-score above 170 was 90% accurate in predicting 6-month disease-free survival. Conclusions: VPA and CRT offered high RR; however, with prohibitive toxicities, which led to early trial termination. Patients and controls had a distinct pattern of miR expression, mainly with low levels of TS miRs targeting Tumor protein P53 (TP53). miR-let-7a/e levels were lower in patients compared to controls, which reinforces the aggressive nature of such tumours (NCT01695122).
  • conferenceObject
    Phase II trial of valproic acid combined with cisplatin-based chemoradiation in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts).
    (2017) MAK, Milena Perez; PASINI, Fatima Solange; DIAO, Lixia; GARCIA, Fabyane Oliveira Teixeira; TAKAHASHI, Tiago Kenji; AMADIO, Alex Vitorio; SIQUEIRA, Sheila Aparecida Coelho; SICHERO, Laura; SNITCOVSKY, Igor M. L.; KULCSAR, Marco Aurelio Vamondes; WANG, Jing; CASTRO, Gilberto